Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 18 of 18 entries
View as:

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01539642 Org: User:
Start: 02/29/12 End: 02/28/13 Due: 02/28/14

A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain

Phase: N/A Priority: Normal
NCT ID: NCT00833040 Org: User:
Start: 04/30/09 End: 03/31/10 Due: 03/31/11

Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain

Phase: N/A Priority: Normal
NCT ID: NCT02447848 Org: User:
Start: 10/31/15 End: 07/31/16 Due: 07/31/17

A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00718081 Org: User:
Start: 08/31/08 End: 03/31/09 Due: 03/31/10

A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery

Phase: N/A Priority: Normal
NCT ID: NCT02356588 Org: User:
Start: 02/28/15 End: 08/31/15 Due: 08/31/16

A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain

Phase: N/A Priority: Normal
NCT ID: NCT01539538 Org: User:
Start: 04/30/12 End: 12/31/12 Due: 12/31/13

A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement

Phase: N/A Priority: Normal
NCT ID: NCT00612534 Org: User:
Start: 03/31/08 End: 10/31/08 Due: 10/31/09

An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement

Phase: N/A Priority: Normal
NCT ID: NCT00859313 Org: User:
Start: 04/30/09 End: 08/31/09 Due: 08/31/10

Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab

Phase: N/A Priority: Normal
NCT ID: NCT01761565 Org: User:
Start: 01/31/13 End: 02/28/13 Due: 02/28/14

Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy

Phase: N/A Priority: Normal
NCT ID: NCT01710345 Org: User:
Start: 10/31/12 End: 02/28/13 Due: 02/28/14

Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02082236 Org: User:
Start: 05/31/14 End: 05/31/14 Due: 05/31/15

Effect of Delivery Route on PK of Sufentanil NanoTab

Phase: N/A Priority: Normal
NCT ID: NCT01639729 Org: User:
Start: 07/31/12 End: 07/31/12 Due: 07/31/13

A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure

Phase: N/A Priority: Normal
NCT ID: NCT00894699 Org: User:
Start: 06/30/09 End: 09/30/09 Due: 09/30/10

Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg

Phase: N/A Priority: Normal
NCT ID: NCT02662764 Org: User:
Start: 09/28/16 End: 05/05/17 Due: 05/05/18

A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain

Phase: N/A Priority: Normal
NCT ID: NCT02662556 Org: User:
Start: 03/31/16 End: 07/31/16 Due: 07/31/17

Nafamostat Efficacy in Phase 3 Registrational CRRT Study

Phase: N/A Priority: Normal
NCT ID: NCT06150742 Org: User:
Start: 08/15/24 End: 12/31/24 Due: 12/31/25

Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01660763 Org: User:
Start: 08/31/12 End: 05/31/13 Due: 05/31/14

Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics

Phase: N/A Priority: Normal
NCT ID: NCT01721070 Org: User:
Start: 11/30/12 End: 12/31/12 Due: 12/31/13